Roots Analysis
FEBRUARY 27, 2024
On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.
Roots Analysis
FEBRUARY 26, 2024
In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017. Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 2, 2022
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.
pharmaphorum
JANUARY 7, 2021
The biotech would likely struggle to supply without the help of its new big pharma partner, although it has been expanding its production capacity in the last few weeks with the help of contract manufacturers like Wacker and Fareva. The post Bayer joins the COVID-19 vaccine push, backing CureVac shot appeared first on.
The Pharma Data
MARCH 16, 2021
The potential of centrally acting COMT inhibitors has not yet been evaluated in the clinic due to the unavailability of such compounds. In partnering with the Lieber Institute, Boehringer Ingelheim has in-licensed preclinical pipeline candidates, representing a first-in-class approach for targets in neuropsychiatric disorders.
The Pharma Data
MARCH 2, 2021
Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Boehringer Ingelheim will advance the programs further and bring promising candidates into non-clinical and clinical development.
The Pharma Data
JULY 21, 2021
The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. We believe this collaboration will create opportunity to more broadly distribute vaccine doses to people in harder-to-reach communities, especially those on the African continent.”.
Expert insights. Personalized for you.
52 
Let's personalize your content